HOUSTON, TX, USA and VANCOUVER, Canada I September 28, 2019 I ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA’s lead Investigational New Drug (“IND”) candidate at the 2019 American Urological Association (“AUA”) Annual Meeting.
In an oral poster presentation titled, “EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer”, a deeper preclinical characterization of EPI-7386 was presented. The poster shows that, in preclinical studies, EPI-7386 demonstrates:
- Activity in multiple in vitro full length androgen receptor (AR) and AR-V7 splice variant driven cellular models.
- Robust antitumor activity as a single agent and in combination with enzalutamide in the VCaP xenograft prostate cancer model.
- Antitumor activity in enzalutamide-resistant prostate cancer xenograft models, 22Rv1 and LNCaP95, with no antitumor activity, as expected, in a non-functional androgen receptor PC-3 prostate cancer xenograft model.
- Wide therapeutic index as demonstrated by a broad dose response in the VCaP model.
- High plasma exposures in animal studies using a new suspension formulation.
| Abstract ID: |
503P |
| Abstract Title: |
EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for
the treatment of prostate cancer |
| Presenter: |
Ronan Le Moigne, PhD |
| Date: |
Saturday September 28, 2019 |
| Time: |
12:00pm CEST |
| Location: |
Hall 4, Fira Gran Via, Barcelona, Spain |
About ESSA Pharma Inc.
ESSA is a pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer (“CRPC”) in patients whose disease is progressing despite treatment with current therapies. ESSA’s proprietary “aniten” compounds bind to the N-terminal domain of the androgen receptor (“AR”), inhibiting AR driven transcription and the AR signaling pathway in a unique manner which bypasses the drug resistance mechanisms associated with current anti-androgens. The Company is currently progressing IND-enabling studies and expects to file an IND with the FDA for EPI-7386 in the first calendar quarter of 2020. For more information, please visit www.essapharma.com or follow us on Twitter under @ESSAPharma.
About Prostate Cancer
Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide (Globocan, 2018). Adenocarcinoma of the prostate is dependent on androgen for tumor progression and depleting or blocking androgen action has been a mainstay of hormonal treatment for over six decades. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels of testosterone, disease progression despite castrate levels of testosterone generally represents a transition to the lethal variant of the disease, metastatic CPRC (“mCRPC”), and most patients ultimately succumb to the illness. The treatment of mCRPC patients has evolved rapidly over the past five years. Despite these advances, additional treatment options are needed to improve clinical outcomes in patients, particularly those who fail existing treatments including abiraterone or enzalutamide, or those who have contraindications to receive those drugs. Over time, patients with mCRPC generally experience continued disease progression, worsening pain, leading to substantial morbidity and limited survival rates. In both in vitro and in vivo animal studies, ESSA’s novel approach to blocking the androgen pathway has been shown to be effective in blocking tumor growth when current therapies are no longer effective.
SOURCE: Essa Pharma
Post Views: 93
HOUSTON, TX, USA and VANCOUVER, Canada I September 28, 2019 I ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA’s lead Investigational New Drug (“IND”) candidate at the 2019 American Urological Association (“AUA”) Annual Meeting.
In an oral poster presentation titled, “EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer”, a deeper preclinical characterization of EPI-7386 was presented. The poster shows that, in preclinical studies, EPI-7386 demonstrates:
- Activity in multiple in vitro full length androgen receptor (AR) and AR-V7 splice variant driven cellular models.
- Robust antitumor activity as a single agent and in combination with enzalutamide in the VCaP xenograft prostate cancer model.
- Antitumor activity in enzalutamide-resistant prostate cancer xenograft models, 22Rv1 and LNCaP95, with no antitumor activity, as expected, in a non-functional androgen receptor PC-3 prostate cancer xenograft model.
- Wide therapeutic index as demonstrated by a broad dose response in the VCaP model.
- High plasma exposures in animal studies using a new suspension formulation.
| Abstract ID: |
503P |
| Abstract Title: |
EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for
the treatment of prostate cancer |
| Presenter: |
Ronan Le Moigne, PhD |
| Date: |
Saturday September 28, 2019 |
| Time: |
12:00pm CEST |
| Location: |
Hall 4, Fira Gran Via, Barcelona, Spain |
About ESSA Pharma Inc.
ESSA is a pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer (“CRPC”) in patients whose disease is progressing despite treatment with current therapies. ESSA’s proprietary “aniten” compounds bind to the N-terminal domain of the androgen receptor (“AR”), inhibiting AR driven transcription and the AR signaling pathway in a unique manner which bypasses the drug resistance mechanisms associated with current anti-androgens. The Company is currently progressing IND-enabling studies and expects to file an IND with the FDA for EPI-7386 in the first calendar quarter of 2020. For more information, please visit www.essapharma.com or follow us on Twitter under @ESSAPharma.
About Prostate Cancer
Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide (Globocan, 2018). Adenocarcinoma of the prostate is dependent on androgen for tumor progression and depleting or blocking androgen action has been a mainstay of hormonal treatment for over six decades. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels of testosterone, disease progression despite castrate levels of testosterone generally represents a transition to the lethal variant of the disease, metastatic CPRC (“mCRPC”), and most patients ultimately succumb to the illness. The treatment of mCRPC patients has evolved rapidly over the past five years. Despite these advances, additional treatment options are needed to improve clinical outcomes in patients, particularly those who fail existing treatments including abiraterone or enzalutamide, or those who have contraindications to receive those drugs. Over time, patients with mCRPC generally experience continued disease progression, worsening pain, leading to substantial morbidity and limited survival rates. In both in vitro and in vivo animal studies, ESSA’s novel approach to blocking the androgen pathway has been shown to be effective in blocking tumor growth when current therapies are no longer effective.
SOURCE: Essa Pharma
Post Views: 93
